Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Schöll M[au]:

Search results

Items: 1 to 50 of 145

1.

Synaptic vesicle protein 2A as a potential biomarker in synaptopathies.

Heurling K, Ashton NJ, Leuzy A, Zimmer ER, Blennow K, Zetterberg H, Eriksson J, Lubberink M, Schöll M.

Mol Cell Neurosci. 2019 Jun;97:34-42. doi: 10.1016/j.mcn.2019.02.001. Epub 2019 Feb 20. Review.

2.

A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease.

Ashton NJ, Nevado-Holgado AJ, Barber IS, Lynham S, Gupta V, Chatterjee P, Goozee K, Hone E, Pedrini S, Blennow K, Schöll M, Zetterberg H, Ellis KA, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Aarsland D, Powell J, Lovestone S, Martins R, Hye A.

Sci Adv. 2019 Feb 6;5(2):eaau7220. doi: 10.1126/sciadv.aau7220. eCollection 2019 Feb.

3.

A walk through tau therapeutic strategies.

Jadhav S, Avila J, Schöll M, Kovacs GG, Kövari E, Skrabana R, Evans LD, Kontsekova E, Malawska B, de Silva R, Buee L, Zilka N.

Acta Neuropathol Commun. 2019 Feb 15;7(1):22. doi: 10.1186/s40478-019-0664-z. Review.

4.

Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer's disease.

Mattsson N, Insel PS, Donohue M, Jögi J, Ossenkoppele R, Olsson T, Schöll M, Smith R, Hansson O.

Alzheimers Dement. 2019 Apr;15(4):570-580. doi: 10.1016/j.jalz.2018.12.001. Epub 2019 Jan 25.

PMID:
30639421
5.

Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration.

Ashton NJ, Leuzy A, Lim YM, Troakes C, Hortobágyi T, Höglund K, Aarsland D, Lovestone S, Schöll M, Blennow K, Zetterberg H, Hye A.

Acta Neuropathol Commun. 2019 Jan 9;7(1):5. doi: 10.1186/s40478-018-0649-3.

6.

Biomarkers for tau pathology.

Schöll M, Maass A, Mattsson N, Ashton NJ, Blennow K, Zetterberg H, Jagust W.

Mol Cell Neurosci. 2019 Jun;97:18-33. doi: 10.1016/j.mcn.2018.12.001. Epub 2018 Dec 7. Review.

7.

Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease.

Vogel JW, Mattsson N, Iturria-Medina Y, Strandberg OT, Schöll M, Dansereau C, Villeneuve S, van der Flier WM, Scheltens P, Bellec P, Evans AC, Hansson O, Ossenkoppele R; Alzheimer's Disease Neuroimaging Initiative; Swedish BioFINDER Study.

Hum Brain Mapp. 2019 Feb 1;40(2):638-651. doi: 10.1002/hbm.24401. Epub 2018 Oct 19.

PMID:
30368979
8.

Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders.

Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Schöll M, Strandberg O, Palmqvist S, Mattsson N, Janelidze S, Santillo A, Ohlsson T, Jögi J, Tsai R, La Joie R, Kramer J, Boxer AL, Gorno-Tempini ML, Miller BL, Choi JY, Ryu YH, Lyoo CH, Hansson O.

JAMA. 2018 Sep 18;320(11):1151-1162. doi: 10.1001/jama.2018.12917.

9.

In vivo Detection of Alzheimer's Disease.

Leuzy A, Heurling K, Ashton NJ, Schöll M, Zimmer ER.

Yale J Biol Med. 2018 Sep 21;91(3):291-300. eCollection 2018 Sep. Review.

10.

Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease.

Mattsson N, Eriksson O, Lindberg O, Schöll M, Lampinen B, Nilsson M, Insel PS, Lautner R, Strandberg O, van Westen D, Zetterberg H, Blennow K, Palmqvist S, Stomrud E, Hansson O.

Neurobiol Aging. 2018 Nov;71:81-90. doi: 10.1016/j.neurobiolaging.2018.07.003. Epub 2018 Jul 11.

PMID:
30107289
11.

Regional times to equilibria and their impact on semi-quantification of [18F]AV-1451 uptake.

Heurling K, Smith R, Strandberg OT, Schain M, Ohlsson T, Hansson O, Schöll M.

J Cereb Blood Flow Metab. 2018 Aug 3:271678X18791430. doi: 10.1177/0271678X18791430. [Epub ahead of print]

PMID:
30073880
12.

Molecular properties underlying regional vulnerability to Alzheimer's disease pathology.

Grothe MJ, Sepulcre J, Gonzalez-Escamilla G, Jelistratova I, Schöll M, Hansson O, Teipel SJ; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2018 Sep 1;141(9):2755-2771. doi: 10.1093/brain/awy189.

13.

No association of salivary total tau concentration with Alzheimer's disease.

Ashton NJ, Ide M, Schöll M, Blennow K, Lovestone S, Hye A, Zetterberg H.

Neurobiol Aging. 2018 Oct;70:125-127. doi: 10.1016/j.neurobiolaging.2018.06.014. Epub 2018 Jun 20.

PMID:
30007161
14.

Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment.

Gonzales MM, Insel PS, Nelson C, Tosun D, Schöll M, Mattsson N, Sacuiu S, Bickford D, Weiner MW, Mackin RS; Alzheimer's Disease Neuroimaging Initiative.

Int J Geriatr Psychiatry. 2018 Oct;33(10):1305-1311. doi: 10.1002/gps.4926. Epub 2018 Jun 28.

PMID:
29953668
15.

Update on biomarkers for amyloid pathology in Alzheimer's disease.

Ashton NJ, Schöll M, Heurling K, Gkanatsiou E, Portelius E, Höglund K, Brinkmalm G, Hye A, Blennow K, Zetterberg H.

Biomark Med. 2018 Jul;12(7):799-812. doi: 10.2217/bmm-2017-0433. Epub 2018 Jun 15.

PMID:
29902934
16.

Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study.

Thordardottir S, Rodriguez-Vieitez E, Almkvist O, Ferreira D, Saint-Aubert L, Kinhult-Ståhlbom A, Thonberg H, Schöll M, Westman E, Wall A, Eriksdotter M, Zetterberg H, Blennow K, Nordberg A, Graff C.

Alzheimers Res Ther. 2018 May 10;10(1):45. doi: 10.1186/s13195-018-0374-y.

17.

18F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies.

Smith R, Schöll M, Londos E, Ohlsson T, Hansson O.

Sci Rep. 2018 Mar 16;8(1):4717. doi: 10.1038/s41598-018-23041-x.

18.

Comparing 18F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease.

Mattsson N, Smith R, Strandberg O, Palmqvist S, Schöll M, Insel PS, Hägerström D, Ohlsson T, Zetterberg H, Blennow K, Jögi J, Hansson O.

Neurology. 2018 Jan 30;90(5):e388-e395. doi: 10.1212/WNL.0000000000004887. Epub 2018 Jan 10.

19.

Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity.

Palmqvist S, Schöll M, Strandberg O, Mattsson N, Stomrud E, Zetterberg H, Blennow K, Landau S, Jagust W, Hansson O.

Nat Commun. 2017 Oct 31;8(1):1214. doi: 10.1038/s41467-017-01150-x.

20.

Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease.

Schöll M, Ossenkoppele R, Strandberg O, Palmqvist S; Swedish BioFINDER study, Jögi J, Ohlsson T, Smith R, Hansson O.

Brain. 2017 Sep 1;140(9):2286-2294. doi: 10.1093/brain/awx171.

PMID:
29050382
21.

[Research for us! Which Topics are Relevant for Patients with Depression?]

Bernges T, Iden L, Gielen R, Scholl M, Brütt AL.

Psychiatr Prax. 2018 Oct;45(7):383-386. doi: 10.1055/s-0043-118147. Epub 2017 Aug 29. German.

PMID:
28850999
22.

In vivo retention of 18F-AV-1451 in corticobasal syndrome.

Smith R, Schöll M, Widner H, van Westen D, Svenningsson P, Hägerström D, Ohlsson T, Jögi J, Nilsson C, Hansson O.

Neurology. 2017 Aug 22;89(8):845-853. doi: 10.1212/WNL.0000000000004264. Epub 2017 Jul 28.

23.

18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease.

Mattsson N, Schöll M, Strandberg O, Smith R, Palmqvist S, Insel PS, Hägerström D, Ohlsson T, Zetterberg H, Jögi J, Blennow K, Hansson O.

EMBO Mol Med. 2017 Sep;9(9):1212-1223. doi: 10.15252/emmm.201707809.

24.

Reassessing rainfall in the Luquillo Mountains, Puerto Rico: Local and global ecohydrological implications.

Murphy SF, Stallard RF, Scholl MA, González G, Torres-Sánchez AJ.

PLoS One. 2017 Jul 7;12(7):e0180987. doi: 10.1371/journal.pone.0180987. eCollection 2017.

25.

Linking Amyloid-β and Tau Deposition in Alzheimer Disease.

Vemuri P, Schöll M.

JAMA Neurol. 2017 Jul 1;74(7):766-768. doi: 10.1001/jamaneurol.2017.0323. No abstract available.

PMID:
28558092
26.

Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks.

Hansson O, Grothe MJ, Strandberg TO, Ohlsson T, Hägerström D, Jögi J, Smith R, Schöll M.

Front Neurosci. 2017 Mar 31;11:167. doi: 10.3389/fnins.2017.00167. eCollection 2017.

27.

Amyloid and tau PET demonstrate region-specific associations in normal older people.

Lockhart SN, Schöll M, Baker SL, Ayakta N, Swinnerton KN, Bell RK, Mellinger TJ, Shah VD, O'Neil JP, Janabi M, Jagust WJ.

Neuroimage. 2017 Apr 15;150:191-199. doi: 10.1016/j.neuroimage.2017.02.051. Epub 2017 Feb 21.

28.

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy.

Smith R, Schöll M, Honer M, Nilsson CF, Englund E, Hansson O.

Acta Neuropathol. 2017 Jan;133(1):149-151. doi: 10.1007/s00401-016-1650-1. Epub 2016 Nov 29. No abstract available.

29.

Increased basal ganglia binding of 18 F-AV-1451 in patients with progressive supranuclear palsy.

Smith R, Schain M, Nilsson C, Strandberg O, Olsson T, Hägerström D, Jögi J, Borroni E, Schöll M, Honer M, Hansson O.

Mov Disord. 2017 Jan;32(1):108-114. doi: 10.1002/mds.26813. Epub 2016 Oct 6.

30.

Large field-of-view movement-compensated intrinsic optical signal imaging for the characterization of the haemodynamic response to spreading depolarizations in large gyrencephalic brains.

Schöll MJ, Santos E, Sanchez-Porras R, Kentar M, Gramer M, Silos H, Zheng Z, Gang Y, Strong AJ, Graf R, Unterberg A, Sakowitz OW, Dickhaus H.

J Cereb Blood Flow Metab. 2017 May;37(5):1706-1719. doi: 10.1177/0271678X16668988. Epub 2016 Jan 1.

31.

18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers.

Smith R, Puschmann A, Schöll M, Ohlsson T, van Swieten J, Honer M, Englund E, Hansson O.

Brain. 2016 Sep;139(Pt 9):2372-9. doi: 10.1093/brain/aww163. Epub 2016 Jun 29.

32.

The continuum of spreading depolarizations in acute cortical lesion development: Examining Leão's legacy.

Hartings JA, Shuttleworth CW, Kirov SA, Ayata C, Hinzman JM, Foreman B, Andrew RD, Boutelle MG, Brennan KC, Carlson AP, Dahlem MA, Drenckhahn C, Dohmen C, Fabricius M, Farkas E, Feuerstein D, Graf R, Helbok R, Lauritzen M, Major S, Oliveira-Ferreira AI, Richter F, Rosenthal ES, Sakowitz OW, Sánchez-Porras R, Santos E, Schöll M, Strong AJ, Urbach A, Westover MB, Winkler MK, Witte OW, Woitzik J, Dreier JP.

J Cereb Blood Flow Metab. 2017 May;37(5):1571-1594. doi: 10.1177/0271678X16654495. Epub 2016 Jan 1. Review.

33.

Recording, analysis, and interpretation of spreading depolarizations in neurointensive care: Review and recommendations of the COSBID research group.

Dreier JP, Fabricius M, Ayata C, Sakowitz OW, William Shuttleworth C, Dohmen C, Graf R, Vajkoczy P, Helbok R, Suzuki M, Schiefecker AJ, Major S, Winkler MK, Kang EJ, Milakara D, Oliveira-Ferreira AI, Reiffurth C, Revankar GS, Sugimoto K, Dengler NF, Hecht N, Foreman B, Feyen B, Kondziella D, Friberg CK, Piilgaard H, Rosenthal ES, Westover MB, Maslarova A, Santos E, Hertle D, Sánchez-Porras R, Jewell SL, Balança B, Platz J, Hinzman JM, Lückl J, Schoknecht K, Schöll M, Drenckhahn C, Feuerstein D, Eriksen N, Horst V, Bretz JS, Jahnke P, Scheel M, Bohner G, Rostrup E, Pakkenberg B, Heinemann U, Claassen J, Carlson AP, Kowoll CM, Lublinsky S, Chassidim Y, Shelef I, Friedman A, Brinker G, Reiner M, Kirov SA, Andrew RD, Farkas E, Güresir E, Vatter H, Chung LS, Brennan KC, Lieutaud T, Marinesco S, Maas AI, Sahuquillo J, Dahlem MA, Richter F, Herreras O, Boutelle MG, Okonkwo DO, Bullock MR, Witte OW, Martus P, van den Maagdenberg AM, Ferrari MD, Dijkhuizen RM, Shutter LA, Andaluz N, Schulte AP, MacVicar B, Watanabe T, Woitzik J, Lauritzen M, Strong AJ, Hartings JA.

J Cereb Blood Flow Metab. 2017 May;37(5):1595-1625. doi: 10.1177/0271678X16654496. Epub 2016 Jan 1. Review.

34.

Changes in electrocorticographic beta frequency components precede spreading depolarization in patients with acute brain injury.

Hertle DN, Heer M, Santos E, Schöll M, Kowoll CM, Dohmen C, Diedler J, Veltkamp R, Graf R, Unterberg AW, Sakowitz OW.

Clin Neurophysiol. 2016 Jul;127(7):2661-7. doi: 10.1016/j.clinph.2016.04.026. Epub 2016 May 4.

35.

Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology.

Insel PS, Mattsson N, Mackin RS, Schöll M, Nosheny RL, Tosun D, Donohue MC, Aisen PS, Jagust WJ, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2016 May 17;86(20):1887-96. doi: 10.1212/WNL.0000000000002683. Epub 2016 Apr 15.

36.

Ketamine modulation of the haemodynamic response to spreading depolarization in the gyrencephalic swine brain.

Sánchez-Porras R, Santos E, Schöll M, Kunzmann K, Stock C, Silos H, Unterberg AW, Sakowitz OW.

J Cereb Blood Flow Metab. 2017 May;37(5):1720-1734. doi: 10.1177/0271678X16646586. Epub 2016 Jan 1.

37.

Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.

Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, O'Neil JP, Janabi M, Lazaris A, Cantwell A, Vogel J, Santos M, Miller ZA, Bettcher BM, Vossel KA, Kramer JH, Gorno-Tempini ML, Miller BL, Jagust WJ, Rabinovici GD.

Brain. 2016 May;139(Pt 5):1551-67. doi: 10.1093/brain/aww027. Epub 2016 Mar 8.

38.

PET Imaging of Tau Deposition in the Aging Human Brain.

Schöll M, Lockhart SN, Schonhaut DR, O'Neil JP, Janabi M, Ossenkoppele R, Baker SL, Vogel JW, Faria J, Schwimmer HD, Rabinovici GD, Jagust WJ.

Neuron. 2016 Mar 2;89(5):971-982. doi: 10.1016/j.neuron.2016.01.028.

39.

Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease.

Rodriguez-Vieitez E, Carter SF, Chiotis K, Saint-Aubert L, Leuzy A, Schöll M, Almkvist O, Wall A, Långström B, Nordberg A.

J Nucl Med. 2016 Jul;57(7):1071-7. doi: 10.2967/jnumed.115.168732. Epub 2016 Feb 16.

40.

Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.

Rodriguez-Vieitez E, Saint-Aubert L, Carter SF, Almkvist O, Farid K, Schöll M, Chiotis K, Thordardottir S, Graff C, Wall A, Långström B, Nordberg A.

Brain. 2016 Mar;139(Pt 3):922-36. doi: 10.1093/brain/awv404. Epub 2016 Jan 26.

41.

Complications during intrahospital transport of critically ill patients: Focus on risk identification and prevention.

Knight PH, Maheshwari N, Hussain J, Scholl M, Hughes M, Papadimos TJ, Guo WA, Cipolla J, Stawicki SP, Latchana N.

Int J Crit Illn Inj Sci. 2015 Oct-Dec;5(4):256-64. doi: 10.4103/2229-5151.170840. Review.

42.

Early astrocytosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer positron emission tomography.

Schöll M, Carter SF, Westman E, Rodriguez-Vieitez E, Almkvist O, Thordardottir S, Wall A, Graff C, Långström B, Nordberg A.

Sci Rep. 2015 Nov 10;5:16404. doi: 10.1038/srep16404.

43.

Multimodality Imaging Approaches in Alzheimer's disease. Part II: 1H MR spectroscopy, FDG PET and Amyloid PET.

Promteangtrong C, Kolber M, Ramchandra P, Moghbel M, Houshmand S, Schöll M, Werner TJ, Alavi A, Buchpiguel C.

Dement Neuropsychol. 2015 Oct-Dec;9(4):330-342. doi: 10.1590/1980-57642015DN94000330. Review.

44.

Multimodality Imaging Approach in Alzheimer disease. Part I: Structural MRI, Functional MRI, Diffusion Tensor Imaging and Magnetization Transfer Imaging.

Promteangtrong C, Kolber M, Ramchandra P, Moghbel M, Houshmand S, Schöll M, Bai H, Werner TJ, Alavi A, Buchpiguel C.

Dement Neuropsychol. 2015 Oct-Dec;9(4):318-329. doi: 10.1590/1980-57642015DN94000318. Review.

45.

High Mercury Wet Deposition at a "Clean Air" Site in Puerto Rico.

Shanley JB, Engle MA, Scholl M, Krabbenhoft DP, Brunette R, Olson ML, Conroy ME.

Environ Sci Technol. 2015 Oct 20;49(20):12474-82. doi: 10.1021/acs.est.5b02430. Epub 2015 Sep 29.

PMID:
26368125
46.

Fluorodeoxyglucose PET in Neurology and Psychiatry.

Schöll M, Damián A, Engler H.

PET Clin. 2014 Oct;9(4):371-90, v. doi: 10.1016/j.cpet.2014.07.005. Epub 2014 Aug 12. Review.

PMID:
26050943
47.

Amyloid biomarkers in Alzheimer's disease.

Blennow K, Mattsson N, Schöll M, Hansson O, Zetterberg H.

Trends Pharmacol Sci. 2015 May;36(5):297-309. doi: 10.1016/j.tips.2015.03.002. Epub 2015 Apr 1. Review.

PMID:
25840462
48.

Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics.

Prestia A, Caroli A, Wade SK, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen CE, Wall A, Carter SF, Schöll M, Choo IH, Nordberg A, Scheltens P, Frisoni GB.

Alzheimers Dement. 2015 Oct;11(10):1191-201. doi: 10.1016/j.jalz.2014.12.001. Epub 2015 Jan 31.

PMID:
25646957
49.

Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression.

Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen C, Wall AE, Carter SF, Schöll M, Choo IH, Grimmer T, Redolfi A, Nordberg A, Scheltens P, Drzezga A, Frisoni GB; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2015 Feb 3;84(5):508-15. doi: 10.1212/WNL.0000000000001209. Epub 2015 Jan 7.

50.

Astrocytosis measured by ¹¹C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients.

Choo IL, Carter SF, Schöll ML, Nordberg A.

Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2120-6. doi: 10.1007/s00259-014-2859-7. Epub 2014 Jul 31.

PMID:
25077930

Supplemental Content

Loading ...
Support Center